Companies Cryptocurrencies
Entasis Therapeutics Holdings Inc
Entasis Therapeutics Holdings Inc
Exchange: NasdaqGM
IPO Date: 26/09/2018
CEO: Dr. Manoussos Perros
Biotechnology Healthcare 🔗
  • ETTX
  • 2.19
  • 104795448
    market cap
  • -0.00999999
If you bought

shares of Entasis Therapeutics Holdings Inc (ETTX) on
You would have made
Old Price $12 Current Price $12

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 33 full-time employees. The firm is focused on the discovery, development and commercialization of antibacterial products to treat infections caused by multi-drug resistant Gram-negative bacteria. Its lead product candidate ETX2514 and its other product candidate ETX0282 inhibits bacterial resistance, b-lactamase enzyme. Its pipeline includes ETX2514UL, ETX0282CPDp, Zoliflodacin, and non-beta (b)-lactam inhibitors of the penicillin-binding proteins (NBP) Program. ETX2514SUL is a fixed-dose combination of ETX2514 with sulbactam, as a novel IV antibiotic with broad spectrum b-lactamase coverage. Zoliflodacin as a single dose, oral antibiotic monotherapy. ETX0282CPDP is an oral fixed-dose combination of ETX0282 with cefpodoxime proxetil. The firm is developing a class of antibiotics with its NBP program in which it is designing molecules for optimal activity against the penicillin-binding proteins (PBP) enzymes.

Address: 35 Gatehouse Dr Waltham MASSACHUSETTS 02451

Stay updated.